Darker cells mean a higher score for this topic on that metric.
LessMore
Last reviewed Sources & creditsMedia creditsMethodology
Quick answers
What was Theranos supposed to do?
The company claimed its devices could run a broad menu of clinical laboratory tests from a finger-stick or other small sample, faster and cheaper than a conventional venous draw sent to a central lab.
When did the public case break?
The Wall Street Journal published John Carreyrou’s first major investigation on 15 October 2015. CMS sanctions, SEC charges (2018), and criminal trials followed.
What was Elizabeth Holmes convicted of?
On 3 January 2022 a Northern District of California jury convicted her of conspiracy to commit wire fraud and three counts of wire fraud involving investors. She was acquitted on several other counts, including patient-related wire-fraud counts.
What sentence did she receive?
Judge Edward J. Davila sentenced Holmes on 18 November 2022 to 135 months (11 years and 3 months) in federal prison, plus supervised release and restitution to be determined in the judgment papers.
What happened to Sunny Balwani?
Ramesh Balwani was convicted in July 2022 on all twelve counts he faced, including investor and patient-related fraud, and was sentenced in December 2022 to 155 months.
Did patients receive inaccurate results?
CMS findings and trial evidence included inaccurate or unreliable results from the Newark lab. Holmes was not convicted on the patient-fraud counts; Balwani was. Civil and regulatory files address laboratory quality separately from those verdicts.
Theranos did not produce a Sarbanes–Oxley-scale statute. It did change how journalists and limited partners talk about ‘stealth’ medical devices.
Culturally it is one of the most adapted Silicon Valley frauds: book, podcast, documentary, and scripted series.
Law & institutions
- CLIA enforcement visibility — The CMS file became a teaching example of how laboratory sanctions can halt a consumer offering even before a criminal verdict.
- FDA and laboratory-developed tests — The case is cited in later debates on LDT oversight and when a ‘device’ story must meet device rules — a policy argument, not a Theranos-specific new Act.
- SEC vs. startup storytelling — The 2018 complaint is used in securities-law teaching as a private-company fraud fact pattern: projected military and pharma validation that was not real.
- Wire-fraud and mixed verdicts — Holmes’s split result is cited on how juries may separate investor schemes from patient schemes on the same facts.
Culture
- Bad Blood — Carreyrou’s 2018 book became the English-language default narrative, the way McLean–Elkind did for Enron.
- The Dropout and later series — Scripted adaptations fixed the turtleneck and voice in popular memory, sometimes ahead of the verdict form.
- Board prestige as a red flag — The famous-statesmen board is now a stock example of social proof that is not scientific diligence.
- Gendered coverage debate — English-language media studies still argue over how much early praise and later scorn tracked Holmes’s gender versus the claims.
Money & scale
- ~$9 billion (2014 press) — A private mark used in magazines. It was not a public-market cap and was not cash in the bank.
- More than $700 million raised — Trial and SEC papers describe hundreds of millions of investor money obtained on the technology and partnership story.
- Walgreens write-down — The retailer took losses on the partnership and later litigation; the precise commercial figure is in civil filings, not the criminal judgment.
The impact is cultural more than statutory: a due-diligence parable that still outruns the split jury form.
Public-record encyclopedia. Not legal advice. Not a how-to. Graphic detail is withheld. Wars belong in a separate atlas.